Literature DB >> 26749488

Acquired C797S Mutation upon Treatment with a T790M-Specific Third-Generation EGFR Inhibitor (HM61713) in Non-Small Cell Lung Cancer.

Haa-Na Song1, Ki Sun Jung2, Kwai Han Yoo2, Jinhyun Cho2, Ji Yun Lee2, Sung Hee Lim2, Hae Su Kim2, Jong-Mu Sun2, Se-Hoon Lee2, Jin Seok Ahn2, Keunchil Park2, Yoon-La Choi3, Woongyang Park4, Myung-Ju Ahn5.   

Abstract

T790M mutation is most common resistant mechanism to epidermal growth factor receptor gene (EGFR) tyrosin kinase inhibitor (TKI). Several third-generation EGFR-mutant selective TKI, such as AZD9291 (AstraZeneca), Rociletinib (Clovis), or HM61713 (Hanmi) have been developed. Acquired resistant C797S mutation was known to be one of the resistance mechanisms of AZD9291, which has not been reported for HM61713 yet. This is the first case report of C797S mutation as resistance mechanism of HM61713.
Copyright © 2015 International Association for the Study of Lung Cancer. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  C797S mutation; EGFR; HM61713; T790M mutation

Mesh：

Substances：

Year:  2015        PMID： 26749488     DOI： 10.1016/j.jtho.2015.12.093

Source DB:  PubMed          Journal:  J Thorac Oncol        ISSN： 1556-0864            Impact factor:   15.609


  41 in total

Review 1.  Third-generation epidermal growth factor receptor-tyrosine kinase inhibitors in T790M-positive non-small cell lung cancer: review on emerged mechanisms of resistance.

Authors:  Roberta Minari; Paola Bordi; Marcello Tiseo
Journal:  Transl Lung Cancer Res       Date:  2016-12

Review 2.  Treatment of EGFR T790M-Positive Non-Small Cell Lung Cancer.

Authors:  Joan Rou-En Choo; Chee-Seng Tan; Ross A Soo
Journal:  Target Oncol       Date:  2018-04       Impact factor: 4.493

3.  Elucidation of radiation-resistant clones by a serial study of intratumor heterogeneity before and after stereotactic radiotherapy in lung cancer.

Authors:  Takahiro Nakagomi; Taichiro Goto; Yosuke Hirotsu; Daichi Shikata; Kenji Amemiya; Toshio Oyama; Hitoshi Mochizuki; Masao Omata
Journal:  J Thorac Dis       Date:  2017-07       Impact factor: 2.895

Review 4.  Resistance to epidermal growth factor receptor tyrosine kinase inhibitors, T790M, and clinical trials.

Authors:  G M O'Kane; T A Barnes; N B Leighl
Journal:  Curr Oncol       Date:  2018-06-13       Impact factor: 3.677

5.  Optimization of Brigatinib as New Wild-Type Sparing Inhibitors of EGFRT790M/C797S Mutants.

Authors:  Shan Li; Tao Zhang; Su-Jie Zhu; Chong Lei; Mengzhen Lai; Lijie Peng; Linjiang Tong; Zilu Pang; Xiaoyun Lu; Jian Ding; Xiaomei Ren; Cai-Hong Yun; Hua Xie; Ke Ding
Journal:  ACS Med Chem Lett       Date:  2022-01-07       Impact factor: 4.345

Review 6.  Potentiating Therapeutic Effects of Epidermal Growth Factor Receptor Inhibition in Triple-Negative Breast Cancer.

Authors:  Kyu Sic You; Yong Weon Yi; Jeonghee Cho; Jeong-Soo Park; Yeon-Sun Seong
Journal:  Pharmaceuticals (Basel)       Date:  2021-06-18

Review 7.  Autochthonous murine models for the study of smoker and never-smoker associated lung cancers.

Authors:  Esra A Akbay; James Kim
Journal:  Transl Lung Cancer Res       Date:  2018-08

8.  Heterogeneity and Coexistence of T790M and T790 Wild-Type Resistant Subclones Drive Mixed Response to Third-Generation Epidermal Growth Factor Receptor Inhibitors in Lung Cancer.

Authors:  Zofia Piotrowska; Mehlika Hazar-Rethinam; Coleen Rizzo; Brandon Nadres; Emily E Van Seventer; Heather A Shahzade; Inga T Lennes; Anthony J Iafrate; Dora Dias-Santagata; Ignaty Leshchiner; Nicholas A Jessop; Haichuan Hu; Subba R Digumarthy; Rebecca J Nagy; Richard B Lanman; Susan Moody; Matthew J Niederst; Jeffrey A Engelman; Aaron N Hata; Ryan B Corcoran; Lecia V Sequist
Journal:  JCO Precis Oncol       Date:  2018-07-16

Review 9.  Mechanisms of resistance to third-generation EGFR tyrosine kinase inhibitors.

Authors:  Shuhang Wang; Yongping Song; Feifei Yan; Delong Liu
Journal:  Front Med       Date:  2016-12-23       Impact factor: 4.592

Review 10.  The safety and efficacy of osimertinib for the treatment of EGFR T790M mutation positive non-small-cell lung cancer.

Authors:  Xin Gao; Xiuning Le; Daniel B Costa
Journal:  Expert Rev Anticancer Ther       Date:  2016-03-21       Impact factor: 4.512
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.